Sino Biological, Inc., a global leader in recombinant technology, announced the launch of SuperNuclease\u00ae Pro (Cat#: SSNP02). This advanced nuclease is engineered to deliver enhanced nucleic acid removal performance for demanding bioprocessing and molecular diagnostic applications. To help researchers evaluate its performance in their workflows, Sino Biological is also introducing a limited-time trial program providing eligible customers with an opportunity to test the solution risk-free.<\/p>\n
Addressing nucleic acid removal challenges in bioprocessing and molecular diagnostics<\/p>\n
Residual nucleic acids are critical impurities that require effective removal during the manufacturing of biological products, including viral vectors, vaccines, and cell and gene therapies. Simultaneously, in the rapidly advancing field of metagenomic Next-Generation Sequencing (mNGS), the overwhelming presence of human host DNA in clinical samples severely compromises pathogen detection sensitivity and inflates sequencing costs. Efficient degradation of DNA and RNA impurities is essential for improving downstream processing efficiency and supporting compliance with increasingly stringent regulatory quality requirements.<\/p>\n
SuperNuclease\u00ae Pro offers enhanced nucleic acid removal<\/p>\n
Building on the foundational SuperNuclease\u00ae, SuperNuclease\u00ae Pro delivers significantly enhanced catalytic activity compared to wild-type Serratia marcescens nuclease across standard cell culture and virus harvest conditions. Crucially for infectious disease diagnostics and high-density processes, SuperNuclease\u00ae Pro maintains exceptional catalytic activity in high-salt environments (e.g., > 300-500 mM NaCl). This unique salt-active property allows for the effective dissociation of chromatin and the removal of host nucleic acids adhered to viral envelopes. By deeply depleting the host genomic background, SuperNuclease\u00ae Pro drastically increases the detection sensitivity of low-titer pathogens and significantly reduces overall NGS sequencing costs. Furthermore, the enzyme demonstrates broad adaptability across diverse pH ranges, temperatures, and magnesium ion concentrations. Its proven thermostability (validated through rigorous 180-day real-time testing at 37 \u00b0C) ensures consistent performance throughout extended bioprocessing and diagnostic workflows.<\/p>\n
A comprehensive nuclease portfolio<\/p>\n
In addition to SuperNuclease\u00ae Pro, Sino Biological offers a comprehensive nuclease portfolio designed to address diverse bioprocessing requirements. This includes GMP-grade SuperNuclease\u00ae products manufactured in accordance with ISO 13485 and GMP quality management systems, as well as specialized Salt Active SuperNuclease\u00ae formulations optimized for high-salt process conditions.<\/p>\n
Apply for the SuperNuclease\u00ae Pro free trial<\/p>\n
Sino Biological\u2019s limited-time trial program enables qualified customers to evaluate SuperNuclease\u00ae Pro in their specific bioprocessing applications prior to full-scale adoption, facilitating faster technology assessment and informed decision-making during process development.<\/p>\n
\nThe launch of SuperNuclease\u00ae Pro reflects our continued commitment to developing innovative solutions that support the evolving needs of bioprocessing and biologics manufacturing. SuperNuclease\u00ae Pro provides researchers with a more powerful tool for hard-to-degrade nucleic acid<\/a> removal. Through our trial program, we are excited to offer customers the opportunity to evaluate its performance firsthand and explore how it can optimize their specific workflows.\u201d<\/p>\n
Dr. Rob Burgess, Chief Business Officer, Sino Biological US, Inc.<\/p>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"Sino Biological, Inc., a global leader in recombinant technology, announced the launch of SuperNuclease\u00ae Pro (Cat#: SSNP02). This…\n","protected":false},"author":2,"featured_media":612913,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[77],"tags":[43450,5505,8658,8626,3286,18,54598,19,17,14965,34674,124884,18334,133,82],"class_list":["post-612912","post","type-post","status-publish","format-standard","has-post-thumbnail","category-science","tag-bioprocessing","tag-cell","tag-diagnostic","tag-diagnostics","tag-dna","tag-eire","tag-gmp","tag-ie","tag-ireland","tag-manufacturing","tag-molecular-diagnostics","tag-nuclease","tag-nucleic-acid","tag-science","tag-technology"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/117013025324676676","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/612912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=612912"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/612912\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/612913"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=612912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=612912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=612912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}